financetom
Business
financetom
/
Business
/
Merger of Leading Firms Creates National Accounting and Advisory Powerhouse Under Richey May Brand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Merger of Leading Firms Creates National Accounting and Advisory Powerhouse Under Richey May Brand
Sep 9, 2025 10:41 AM

DENVER, Sept. 9, 2025 /PRNewswire/ -- A transformative merger has united five respected accounting and advisory firms—WSRP, MKA, Sobul Primes & Schenkel, The Doty Group and Richey May—to form a single, national accounting and advisory platform operating under the Richey May brand. 

This milestone follows more than a year of successful collaboration among the firms. The combination significantly expands the platform's industry reach, geographic footprint, and depth of technical and operational expertise—positioning the unified Richey May to deliver enhanced value to clients across the country. 

Richey May will operate in an alternative practice structure. Operating under the shared Richey May brand, Richey, May & Co., LLP, a licensed CPA firm, will perform attest services, while RM Advisory LLC, which is not a CPA firm, performs nonattest services.  

Jason Yetter will lead RM Advisory as Chief Executive Officer. He will be joined by Dan Rinehart, serving as President of Advisory Services and leader of the Northwest Region; Ed Moss, National Director of Acquisitions, who will lead the Southeast Region; and Abhi Parikh, who will head the Southern California Region. Danny O'Connor will serve as Managing Partner of Richey, May & Co., LLP. 

To learn more about this transformative merger, visit Richey May Merger Announcement. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/merger-of-leading-firms-creates-national-accounting-and-advisory-powerhouse-under-richey-may-brand-302551254.html

SOURCE Richey May

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
VSE Shares Decline After Q1 Results
VSE Shares Decline After Q1 Results
May 9, 2024
02:23 PM EDT, 05/09/2024 (MT Newswires) -- VSE (VSEC) shares were down more than 7% in recent Thursday trading, a day after the company reported Q1 results. VSE booked $0.87 in Q1 adjusted diluted earnings per share, up from $0.71 a year earlier. Analysts polled by Capital IQ expected $0.72. Revenue for the quarter ended March 31 was $241.5 million,...
What's Going On With G1 Therapeutics Stock?
What's Going On With G1 Therapeutics Stock?
May 9, 2024
G1 Therapeutics, Inc. ( GTHX ) shares are trading higher Thursday amid M&A blog speculation of a takeover offer.  What To Know: According to a report from Seeking Alpha, G1 Therapeutics ( GTHX ) has received and rejected multiple offers from TerSera Therapeutics.  According to the report, one offer from TerSera is rumored to have a contingent value right which...
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
May 9, 2024
Thursday, Viatris Inc ( VTRS ) reported first-quarter EPS of $0.67, which is in line with the consensus. The company reported sales of $3.66 billion, missing the consensus of $3.69 billion. Total net sales declined 2% on a reported basis and increased 2% on a divestiture-adjusted operational basis. Brand sales fell 5% to $2.31 billion. The company says the performance reflects strong growth in Emerging Markets...
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
May 9, 2024
Thursday, GoodRx Holdings ( GDRX ) reported a first-quarter adjusted EPS of $0.08, which was in line with the consensus and higher than the $0.07 reported a year ago. The company reported sales of $197.88 million, beating the consensus of $196.08 million. Revenue and Adjusted Revenue increased 8% to $197.9 million compared to $184.0 million.  Prescription transactions revenue increased 8% to $145.4 million, primarily driven by a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved